Utility of ranolazine in chronic stable angina patients.
Chronic stable angina is a debilitating illness affecting at least 6.6 million US residents. Despite being optimally treated by pharmacotherapy and revascularization up to 26% of patients still experience angina. Diabetes mellitus is a common co-morbid condition in angina patients. Several new investigational medications are being tested for chronic angina. Advances in understanding of myocardial ischemia have prompted evaluation of a number of new antianginal strategies. In this review we discuss the utility of ranolazine, a recently approved novel antianginal agent and its efficacy in the diabetic patient population. In addition to its antianginal action in diabetic patients with chronic angina, ranolazine may have favorable effects on glycated hemoglobin levels.
Patel
Pawan D
PD
Department of Cardiology, Chicago Medical School, North Chicago, IL 60064, USA.
Arora
Rohit R
RR
D000083:Acetanilides / Q000009:adverse effects / Q000627:therapeutic use*; D000787:Angina Pectoris / Q000150:complications / Q000188:drug therapy*; D002317:Cardiovascular Agents / Q000009:adverse effects / Q000627:therapeutic use*; D002908:Chronic Disease; D048909:Diabetes Complications / Q000188:drug therapy* / Q000378:metabolism; D006442:Glycated Hemoglobin / Q000378:metabolism; D006801:Humans; D010879:Piperazines / Q000009:adverse effects / Q000627:therapeutic use*; D000069458:Ranolazine; D016896:Treatment Outcome
D000083:Acetanilides; D002317:Cardiovascular Agents; D006442:Glycated Hemoglobin; D010879:Piperazines; D000069458:Ranolazine; C517652:hemoglobin A1c protein, human